VJHemOnc is committed to improving our service to you

COMy 2019 | Proteasome inhibitors-based combinations for elderly MM

VJHemOnc is committed to improving our service to you

Maria-Victoria Mateos

María-Victoria Mateos, MD, PhD, of the University Hospital of Salamanca, Salamanca, Spain, discusses the improvement in proteasome inhibitor-based combinations brought about for the management of newly diagnosed multiple myeloma (MM) in elderly patients. First used with a backbone of melphalan/prednisone, Dr Mateos says that various combinations are being used across the globe to treat this population of patients. Additionally, monoclonal antibodies, for example daratumumab, can be used on top of proteasome inhibitor-based combination of bortezomib, melphalan, prednisone (VMP). This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter